. 2012 Oct;14(10):904–911. doi: 10.1089/dia.2012.0075

Table 4.

Logistic Regressions of Exenatide Use and Health Outcomes on Out-of-Pocket Costs

	Analysis by dependent variable
	Pancreatitis		Pancreatic cancer
	Exenatide use^a	Health outcome	Exenatide use^a	Health outcome
Odds ratio (95% confidence interval)
Constant	0.031 (0.030–0.032)^‡	0.003 (0.002–0.003)^‡	0.011 (0.010–0.011)^‡	0.0007 (0.0006–0.0008)^‡
High out-of-pocket cost^b	0.711 (0.679–0.745)^‡	0.934 (0.835–1.046)	0.672 (0.614–0.735)^‡	1.072 (0.853–1.347)
Predictive margins
Low cost	3.0%	0.256%	1.1%	0.068%
High cost	2.2%	0.239%	0.7%	0.073%
Other statistics
Patient-years (n)	530,574	530,574	419,613	419,613

In pancreatitis analysis, outcome is hospitalization for acute pancreatitis; in pancreatic cancer analysis, outcome is incident pancreatic cancer diagnosis.

^{^a}

Exenatide use is defined for pancreatitis as at least one exenatide prescription filled and for pancreatic cancer as cumulative use of 365+ days as of the prior year.

^{^b}

High out-of-pocket cost is defined as patient cost of 30-day exenatide supply above the median level in the pancreatitis analysis and as cost in the prior year above the median in the pancreatic cancer analysis.

Statistical significance is defined at the ^‡1% level.